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Anticancer activityAbstract As a part of our endeavor toward the synthesis of new heterocyclic bioactive agents, two
series of thiazolidin-4-one fused s-triazines were synthesized by applying an efﬁcient palladium
catalyzed C–C Suzuki coupling using catalyst system Pd(OAC)2, Xphos and K3PO4 as a base in
toluene solvent. Moreover, the synthesized analogs were further screened for their in vitro antimi-
crobial as well as anticancer efﬁcacy against prostate cancer PC3 cells. Some compounds displayed
remarkable antimicrobial activity and noticeable anticancer activity. It was observed that, both
benzonitrile and nicotinonitrile are essential to increase the different pharmacological activities.
The newly synthesized compounds were characterized by IR, 1H NMR, 13C NMR and MS
analysis.
ª 2014 King Saud University. Production and hosting by Elsevier B.V.D license.1. Introduction
Although there are many antibiotics and chemotherapeutics
available since last two decades, the treatment of infectious dis-
eases remains a challenging therapeutic problem due to the
inexorable increase and spread of multidrug-resistant strains.
So as to minimize the rapid multidrug-resistance in pathogenicmicrobes, there is an emergence need for the development of
new classes of antimicrobial agents [1]. A major challenge of
modern drug discovery is the design of highly efﬁcient chemical
reaction sequences which provide a maximum of the structural
complexity and biological diversity with just a minimum num-
ber of synthetic steps to assemble compounds with interesting
properties. It has been reported that, s-triazine ring skeleton
possesses a broad spectrum of biological and pharmaceutical
activities, such as antimicrobial, antifungal, antibacterial, anti-
cancer, anti HIV, anti-inﬂammatory, anti-tuberculosis, antima-
larial etc [2–10]. Moreover, thiazolidin-4-one derivatives are
also reported to have important biological activities such as
anti-inﬂammatory [11], anti-tuberculosis [12], anticancer [13],
antitumor [14], anti-HIV [15], antibacterial [16], antifungal
[17], antioxidant [18], antiviral [19], anticonvulsant [20], diuret-
ics [21], nematicidal [22], antihistaminic [23] activity etc.
Synthesis of new thiazolidin-4-one fused s-triazines 647The palladium catalyzed formation of carbon–carbon
bonds has emerged as an efﬁcient and straight forward
solution for the synthesis of a variety of heterocycles. In recent
years, metal-catalyzed reactions such as Kumada-Corriu [24],
Stille [25], Negishi [26], Buchwald–Hartwig [27], Suzuki–Miya-
ura [28,29] cross-coupling etc have become most reliable and
are widely used in carbon–carbon or carbon–heteroatom bond
generation in natural product synthesis, pharmaceutical chem-
istry, material science and agrochemicals. Here, we report the
synthesis of various benzonitrile/nicotinonitrile and thiazoli-
din-4-one incorporated s-triazine analogs by applying an efﬁ-
cient Pd-catalyzed C–C Suzuki coupling using catalyst
system Pd(OAC)2, Xphos and K3PO4 as a base in toluene sol-
vent. The antimicrobial activity of synthesized analogs has
been carried out against two Gram-positive bacteria, three
Gram-negative bacteria and two fungal species to observe
the variation in biological activity. In addition, the synthesized
analogs were also tested for their efﬁcacy against prostate can-
cer PC3 cells.
2. Experimental
2.1. Chemistry
All reactions were carried out under a nitrogen atmosphere.
Air- and moisture-sensitive solvents and solutions were trans-
ferred via syringe or stainless steel cannula. All chemicals were
purchased from sigma Aldrich, merck and ﬂuka. Solvents used
were of analytical grade. Anhydrous potassium carbonate was
stored in a nitrogen-ﬁlled glovebox, ground and was taken out
in small quantities and stored in a desiccator. All reactions
were routinely checked by TLC. TLC was performed on alu-
minum-backed silica gel plates (silica gel 60 F254 grade, Merck
DC) with spots visualized by UV light. Column chromatogra-
phy was performed on silica gel LC 60A (70–200 micron).
Melting points were determined in open capillaries on a Veego
electronic apparatus VMP–D (Veego Instrument Corporation,
Mumbai, India) and are uncorrected. 1H NMR and 13C NMR
spectra were recorded on a Bruker400 MHz model spectrome-
ter using DMSO-d6 as a solvent and TMS as internal standard
with 1H resonant frequency of 400 MHz and 13C resonant fre-
quency of 100 MHz. The 1H NMR, 13C NMR chemical shifts
were reported as parts per million (ppm) downﬁeld from TMS
(Me4Si). The splitting patterns are designated as follows; s,
singlet; d, doublet; dd, doublet of doublets; t, triplet; m, mul-
tiplet. Elemental analyses (C, H, N) were performed using a
Heraeus Carlo Erba 1180 CHN analyzer (Hanau, Germany).
The mass spectra were measured with Waters Micromass
Q-Tof Micro instrument (time of ﬂight (TOF) mass spectrom-
eter). Column chromatography was performed on 1½ feet
(2.5 cm diameter) glass column using silica gel LC 60A (70–
200 micron).
2.1.1. 2,4-Dichloro-6-(4-methylpiperazin-1-yl)-1,3,5-triazine (2)
An oven-dried schlenk tube was charged with a magnetic stir
bar, 2,4,6-trichloro-1,3,5-triazine 1 (10 mmol), N-methylpiper-
azine (11 mmol), potassium carbonate (11 mmol) and anhy-
drous acetone (30 mL). The tube was then evacuated and
back ﬁlled with nitrogen. The protocol was repeated two times.
The tube was placed in an ice bath at 0–5 C temperature and
the reaction slurry was stirred vigorously for 6 h. At the end ofthe reaction, the reaction mixture was treated with 200 mL ice
cold water, and the resulting precipitate was ﬁltered off. The
crude product 2 was recrystallized from DMF [30]. White
solid, Yield: 89%, mp 193–195 C; IR (KBr, cm1): 2942,
2889 (CH2), 1642 (C‚N), 742 (C–Cl).
1H NMR (400 MHz,
DMSO-d6): d 3.57 (br s, 4H, piperazine), 3.31 (br s, 4H, piper-
azine), 2.29 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d
172.6 (2C, Ctri–Cl) 168.3 (1C, Ctri–Npip), 56.1 (2C, Cpip), 46.7
(2C, Cpip), 40.2 (1C, CH3).2.1.2. 4-(4-Chloro-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-yloxy)benzonitrile (3a)6-(4-chloro-6-
(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yloxy)nicotinonitrile
(3b)
An oven-dried schlenk tube was charged with a magnetic stir
bar, intermediate 2 (10 mmol), 4-hydroxybenzonitrile/6-
hydroxynicotinonitrile (11 mmol), potassium carbonate
(15 mmol) and anhydrous acetone (35 mL). The tube was then
evacuated and back ﬁlled with nitrogen. The protocol was re-
peated two times. The reaction slurry was stirred vigorously at
30 C for 12 h. After the completion of the reaction, the slurry
was treated with 200 mL ice cold water, and the resulting pre-
cipitate was ﬁltered off. The crude product 3a/3b was recrystal-
lized from DMF [31]. (3a) Pale white solid, Yield: 82%, mp
217–219 C; IR (KBr, cm1): 2942, 2889 (CH2), 2237
(C„N), 1239 (C–O–C), 758 (C–Cl). 1H NMR (400 MHz,
DMSO-d6): d 7.68 (dd, J= 7.2, 1.5 Hz, 2H, Ar–H), 7.38
(dd, J= 6.8, 1.8 Hz, 2H, Ar–H), 3.77 (br s, 4H, piperazine),
3.54 (br s, 4H, piperazine), 2.43 (s, 3H, CH3).
13C NMR
(100 MHz, DMSO-d6): d 171.7 (1C, Ctri–O), 170.0 (1C, Ctri–
Cl), 167.1 (1C, Ctri–Npip), 149.2 (1C, Cbenz–O), 133.9 (2C),
125.4 (2C), 119.8 (1C, CN), 106.5 (1C, C–CN), 58.1 (2C, Cpip),
47.9 (2C, Cpip), 39.3 (1C, CH3). (3b) White solid, Yield: 85%,
mp 188–189 C; IR (KBr, cm1): 2930, 2852 (CH2), 2220
(C„N), 1198 (C–O–C), 742 (C–Cl). 1H NMR (400 MHz,
DMSO-d6): d 8.31 (s, 1H, CC–N of benzonitrile), 7.94 (dd,
J= 7.5, 2.0 Hz, 1H, Ar–H), 7.06 (dd, J= 6.8, 1.6 Hz, 1H,
Ar–H), 3.74 (br s, 4H, piperazine), 3.49 (br s, 4H, piperazine),
2.33 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.3
(1C, Ctri–O), 169.6 (1C, Ctri–Cl), 165.2 (1C, Ctri–Npip), 158.4
(1C, Cbenz–O), 152.7, 138.3, 120.6 (1C, CN), 114.3, 108.3
(1C, C–CN), 56.2 (2C, Cpip), 46.8 (2C, Cpip), 41.0 (1C, CH3).
2.1.3. 4-(4-(4-Aminophenyl)-6-(4-methylpiperazin-1-yl)-
1,3,5-triazin-2-yloxy)benzonitrile (4a)/6-(4-(4-aminophenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yloxy)nicotinonitrile
(4b)
An oven-dried 250 mL ﬂat bottom ﬂask was charged with a
magnetic stir bar, intermediate 3a/3b (10 mmol), K3PO4
(15 mmol), ligand L (5 mol%), Pd(OAC)2 (3.0 mol%), 4-amin-
ophneylboronic acid pinacol ester (15 mmol) and toluene
(100 mL). The ﬂask was then evacuated and back ﬁlled with
nitrogen. The protocol was repeated two times. The ﬂask
was placed in a preheated oil bath at reﬂuxed temperature
and the reaction slurry was stirred vigorously for 13 h. The
solvent war recovered at reduced pressure. Then the reaction
mixture was cooled to room temperature. The residue was
dissolved in dichloro methane and ﬁltered through a pad of
Celite. The ﬁltrate was washed with water (2 · 100 mL), and
the organic layer was dried with sodium sulfate. The ﬁltrate
was concentrated and the resulting residue was puriﬁed by col-
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system to yield the desired analog 6 [32]. (4a) White solid,
Yield: 89%, mp 243–247 C; IR (KBr, cm1): 3323 (NH2),
2931, 2847 (CH2), 2224 (C„N), 1256 (C–O–C).
1H NMR
(400 MHz, DMSO-d6): d 7.90 (dd, J= 6.8, 1.7 Hz, 2H, Ar–
H), 7.70–7.56 (m, 4H, Ar–H), 7.30–7.21 (m, 2H, Ar–H), 5.02
(br s, 2H, NH2), 3.69 (br s, 4H, piperazine), 3.46 (br s, 4H,
piperazine), 2.48 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-
d6): d 168.5 (1C, Ctri–O), 165.3 (1C, Ctri–Npip), 163.2 (1C, Ctri–
CPh), 150.7 (1C, Cbenz–O), 146.3 (1C, C–NH2), 134.1 (2C), 131.8
(2C), 127.3, 125.4 (2C), 119.9 (1C, CN), 116.8 (2C), 105.4 (1C,
C–CN), 53.7 (2C, Cpip), 46.1 (2C, Cpip), 42.8 (1C, CH3). (4b)
White solid, Yield: 84%, mp 221–223 C; IR (KBr, cm1):
3417 (NH2), 2955, 2943, 2847 (CH2), 2227 (C„N), 1228 (C–
O–C). 1H NMR (400 MHz, DMSO-d6): d 8.47 (s, 1H, CH–N
of benzonitrile), 8.25 (dd, J= 7.2, 2.2 Hz, 1H, Ar–H), 7.83–
7.47 (m, 5H, Ar–H), 7.19–6.98 (m, 2H, Ar–H), 5.63 (br s, 2H,
NH2), 3.78 (br s, 4H, piperazine), 3.61 (br s, 4H, piperazine),
2.56 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 168.6
(1C, Ctri–O), 165.1 (1C, Ctri–Npip), 164.9 (1C, Ctri–Npip), 159.0
(1C, Cbenz–O), 155.3, 149.6 (1C, C–NH2), 140.6, 129.2 (2C),
124.5, 119.3 (1C, CN), 117.4 (2C), 104.0 (1C, C–CN), 58.5
(2C, Cpip), 47.2 (2C, Cpip), 39.6 (1C, CH3).2.1.4. General synthetic procedure for Schiff bases 6a–g/7a–g
An oven-dried schlenk tube was charged with a magnetic stir
bar, intermediate 4a/4b (2 mmol), various aldehydes 5a–g
(2.5 mmol) and dry toluene (50 mL). The ﬂask was then evac-
uated and back ﬁlled with nitrogen. The protocol was repeated
two times. The ﬂask was placed in a preheated oil bath at re-
ﬂuxed temperature and the reaction slurry was stirred vigor-
ously for 6–8 h. After the completion of the reaction, the
solvent was removed by distillation; solid product obtained
was washed with distilled water, dried and recrystallized from
10% acetone in toluene to afford intermediate Schiff bases 6a–
g/7a–g. The progress of the reaction was monitored by Thin
Layer Chromatography using chloroform: methanol (9:1) sol-
vent system [33].
2.1.4.1. (Z)-4-((4-(4-(benzylideneamino)phenyl)-6-(4-meth-
ylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile (6a). White
solid, Yield: 83%, mp 196–198 C; IR (KBr, cm1): 3028
(CH), 2223 (C„N), 1628 (C‚N), 1244 (C–O–C); 1H NMR
(400 MHz, DMSO-d6): d 8.01 (s, 1H, N‚CH–Ph), 7.53–7.27
(m, 7H, Ar–H), 7.15–6.73 (m, 6H, Ar–H), 3.89 (br s, 4H, piper-
azine), 3.47 (br s, 4H, piperazine), 2.31 (s, 3H, CH3).
2.1.4.2. (Z)-4-((4-(4-((4-chlorobenzylidene)amino)phenyl)-6-
(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile
(6b). Greenish white solid, Yield: 79%, mp 218 C; IR (KBr,
cm1): 2983 (CH), 2238 (C„N), 1632 (C‚N), 1230 (C–O–C);
1H NMR (400 MHz, DMSO-d6): d 8.14 (s, 1H, N‚CH–Ph),
7.67–7.32 (m, 7H, Ar–H), 7.09–6.85 (m, 6H, Ar–H), 3.76 (br
s, 4H, piperazine), 3.51 (br s, 4H, piperazine), 2.39 (s, 3H,
CH3).
2.1.4.3. (Z)-4-((4-(4-((4-bromobenzylidene)amino)phenyl)-6-
(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile
(6c). White solid, Yield: 70%, mp 243–245 C; IR (KBr,
cm1): 3021 (CH), 2214 (C„N), 1619 (C‚N), 1239
(C–O–C); 1H NMR (400 MHz, DMSO-d6): d 8.09 (s, 1H,N‚CH–Ph), 7.69–7.52 (m, 7H, Ar–H), 7.29–6.97 (m, 6H,
Ar–H), 3.80 (br s, 4H, piperazine), 3.58 (br s, 4H, piperazine),
2.28 (s, 3H, CH3).
2.1.4.4. (Z)-4-((4-(4-((4-ﬂuorobenzylidene)amino)phenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile
(6d). White solid, Yield: 75%, mp 211–212 C; IR (KBr,
cm1): 3024 (CH), 2228 (C„N), 1628 (C‚N), 1248
(C–O–C); 1H NMR (400 MHz, DMSO-d6): d 7.93 (s, 1H,
N‚CH–Ph), 7.46–7.19 (m, 7H, Ar–H), 7.04–6.68 (m, 6H,
Ar–H), 3.77 (br s, 4H, piperazine), 3.50 (br s, 4H, piperazine),
2.19 (s, 3H, CH3).
2.1.4.5. (Z)-4-((4-(4-methylpiperazin-1-yl)-6-(4-((4-nitrobenzyli-
dene)amino)phenyl)-1,3,5-triazin-2-yl)oxy)benzonitrile (6e). White
solid, Yield: 83%, mp 219–221 C; IR (KBr, cm1): 3083 (CH),
2230 (C„N), 1643 (C‚N), 1248 (C–O–C); 1H NMR (400MHz,
DMSO-d6): d 8.23 (s, 1H, N‚CH–Ph), 7.38–7.21 (m, 7H, Ar–H),
7.12–6.85 (m, 6H, Ar–H), 3.69 (br s, 4H, piperazine), 3.48 (br s, 4H,
piperazine), 2.36 (s, 3H, CH3).
2.1.4.6. (Z)-4-((4-(4-((4-hydroxybenzylidene)amino)phenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile
(6f). White solid, Yield: 78%, mp 219–221 C; IR (KBr,
cm1): 3027 (CH), 2241 (C„N), 1630 (C‚N), 1248
(C–O–C); 1H NMR (400 MHz, DMSO-d6): d 8.34 (s, 1H,
N‚CH–Ph), 7.59–7.30 (m, 7H, Ar–H), 7.26–6.93 (m, 6H,
Ar–H), 5.37 (1H, OH), 3.74 (br s, 4H, piperazine), 3.52 (br s,
4H, piperazine), 2.45 (s, 3H, CH3).
2.1.4.7. (Z)-4-((4-(4-((4-methoxybenzylidene)amino)phenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)benzonitrile
(6g). White solid, Yield: 72%, mp 219–221 C; IR (KBr,
cm1): 3054 (CH), 2225 (C„N), 1621 (C‚N), 1248 (C–O–C);
1H NMR (400 MHz, DMSO-d6): d 8.11 (s, 1H, N‚CH–Ph),
7.54–7.32 (m, 7H, Ar–H), 7.16–7.01 (m, 6H, Ar–H), 3.97
(1H, OCH3), 3.63 (br s, 4H, piperazine), 3.50 (br s, 4H, piper-
azine), 2.29 (s, 3H, CH3).
2.1.4.8. (Z)-6-((4-(4-(benzylideneamino)phenyl)-6-(4-meth-
ylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)nicotinonitrile (7a).
White solid, Yield: 71%, mp 202–203 C; IR (KBr, cm1):
3038 (CH), 2229 (C„N), 1628 (C‚N), 1231 (C–O–C). 1H
NMR (400 MHz, DMSO-d6): d 8.48 (s, 1H, N‚CH–Ph),
8.19 (s, 1H, CH–N of benzonitrile), 8.03 (dd, J= 6.8,
1.2 Hz, 1H, Ar–H), 7.72–7.41 (m, 5H, Ar–H), 7.25–6.88 (m,
2H, Ar–H), 3.73 (br s, 4H, piperazine), 3.57 (br s, 4H, pipera-
zine), 2.53 (s, 3H, CH3).
2.1.4.9. (Z)-6-((4-(4-((4-chlorobenzylidene)amino)phenyl)
-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)nicotinonit-
rile (7b). White solid, Yield: 67%, mp 213 C; IR (KBr,
cm1): 3113 (CH), 2234 (C„N), 1642 (C‚N), 1240 (C–O–
C). 1H NMR (400 MHz, DMSO-d6): d 8.32 (s, 1H, N‚CH–
Ph), 8.14 (s, 1H, CH–N of benzonitrile), 7.89 (dd, J= 7.2,
1.8 Hz, 1H, Ar–H), 7.61–7.47 (m, 5H, Ar–H), 7.19–6.92 (m,
2H, Ar–H), 3.78 (br s, 4H, piperazine), 3.53 (br s, 4H, pipera-
zine), 2.39 (s, 3H, CH3).
2.1.4.10. (Z)-6-((4-(4-((4-bromobenzylidene)amino)phenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)nicotinonitri-
Synthesis of new thiazolidin-4-one fused s-triazines 649le (7c). White solid, Yield: 67%, mp 229–233 C; IR (KBr,
cm1): 3052 (CH), 2245 (C„N), 1622 (C‚N), 1257
(C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.49 (s, 1H,
N‚CH–Ph), 8.27 (s, 1H, CH–N of benzonitrile), 8.11 (dd,
J= 7.8, 2.1 Hz, 1H, Ar–H), 7.69–7.53 (m, 5H, Ar–H), 7.04–
6.76 (m, 2H, Ar–H), 3.84 (br s, 4H, piperazine), 3.58 (br s,
4H, piperazine), 2.42 (s, 3H, CH3).2.1.4.11. (Z)-6-((4-(4-((4-ﬂuorobenzylidene)amino)phenyl)-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)nicotinonitri-
le (7d). White solid, Yield: 73%, mp 192–193 C; IR (KBr,
cm1): 3107 (CH), 2219 (C„N), 1610 (C‚N), 1234
(C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.35 (s, 1H,
N‚CH–Ph), 8.18 (s, 1H, CH–N of benzonitrile), 7.92 (dd,
J= 7.2, 2.3 Hz, 1H, Ar–H), 7.55–7.31 (m, 5H, Ar–H), 7.13–
6.89 (m, 2H, Ar–H), 3.78 (br s, 4H, piperazine), 3.50 (br s,
4H, piperazine), 2.38 (s, 3H, CH3).2.1.4.12. (Z)-6-((4-(4-methylpiperazin-1-yl)-6-(4-((4-nitro-
benzylidene)amino)phenyl)-1,3,5-triazin-2-yl)oxy)nicotinonit-
rile (7e). White solid, Yield: 78%, mp 239–242 C; IR (KBr,
cm1): 2991 (CH), 2224 (C„N), 1629 (C‚N), 1224 (C–O–
C). 1H NMR (400 MHz, DMSO-d6): d 8.49 (s, 1H, N‚CH–
Ph), 8.33 (s, 1H, CH–N of benzonitrile), 8.19 (dd, J= 6.9,
1.8 Hz, 1H, Ar–H), 7.67–7.42 (m, 5H, Ar–H), 7.21–7.03 (m,
2H, Ar–H), 3.89 (br s, 4H, piperazine), 3.62 (br s, 4H, pipera-
zine), 2.31 (s, 3H, CH3).2.1.4.13. (Z)-6-((4-(4-((4-hydroxybenzylidene)amino)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
nicotinonitrile (7f). White solid, Yield: 80%, mp 215–217 C;
IR (KBr, cm1): 3048 (CH), 2235 (C„N), 1642 (C‚N),
1242 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.28 (s,
1H, N‚CH–Ph), 8.09 (s, 1H, CH–N of benzonitrile), 7.98
(dd, J= 7.2, 2.0 Hz, 1H, Ar–H), 7.61–7.23 (m, 5H, Ar–H),
7.06–6.75 (m, 2H, Ar–H), 5.20 (1H, OH), 3.81 (br s, 4H, piper-
azine), 3.48 (br s, 4H, piperazine), 2.46 (s, 3H, CH3).2.1.4.14. (Z)-6-((4-(4-((4-methoxybenzylidene)amino)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
nicotinonitrile (7g). White solid, Yield: 75%, mp 197 C; IR
(KBr, cm1): 3059 (–CH), 2220 (C„N), 1618 (C‚N), 1230
(C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.37 (s, 1H,
N‚CH–Ph), 8.16 (s, 1H, CH–N of benzonitrile), 7.84 (dd,
J= 8.2, 1.9 Hz, 1H, Ar–H), 7.43–7.16 (m, 5H, Ar–H), 7.01–
6.82 (m, 2H, Ar–H), 3.97 (1H, OCH3), 3.77 (br s, 4H, pipera-
zine), 3.54 (br s, 4H, piperazine), 2.38 (s, 3H, CH3).2.1.5. General synthetic procedure for ﬁnal analogs (8a–g/9a–g)
An oven-dried schlenk tube was charged with a magnetic stir
bar, analogs 5a–g/6a–g (2 mmol), thioglycolic acid (3 mmol),
a pinch of anhydrous zinc chloride and 1,4-dioxane (30 mL).
The tube was then evacuated and back ﬁlled with nitrogen.
The protocol was repeated two times. The tube was placed
in a preheated oil bath at reﬂuxed temperature and the reac-
tion slurry was stirred vigorously for 12–14 h. After the com-
pletion of the reaction, the reaction mass was poured in
crushed ice and the resulting precipitate was ﬁltered, washedwith water, dried and crystallized with a suitable solvent to ob-
tain 8a–g/9a–g. The progress of the reaction was monitored by
Thin Layer Chromatography using n-hexane: ethyl acetate
(8:2) solvent system [34].
2.1.5.1. 4-(4-(4-Methylpiperazin-
1-yl)-6-(4-(4-oxo-2-phenylthiazolidin-3-yl)phenyl)-
1,3,5-triazin-2-yloxy)benzonitrile (8a). White solid, Yield:
78%, mp 255–257 C; IR (KBr, cm1): 3039 (CH), 2228
(C„N), 1724 (C‚O), 1256 (C–O–C). 1H NMR (400 MHz,
DMSO-d6): d 8.18 (dd, J= 8.2, 2.4 Hz, 2H, Ar–H), 7.71–
7.55 (m, 9H, Ar–H), 7.15–7.13 (m, 2H, Ar–H), 6.15 (s, 1H,
S–CH–N), 3.82 (d, J= 2.8 Hz, 1H, S–CH2), 3.79 (d,
J= 4.2 Hz, 1H, S–CH2), 3.72 (br s, 4H, piperazine), 3.52 (br
s, 4H, piperazine), 2.71 (s, 3H, CH3).
13C NMR (100 MHz,
DMSO-d6): d 172.3 (1C, C‚O), 168.4 (1C, Ctri–O), 165.7
(1C, Ctri–Npip), 160.0 (1C, Ctri–CPh), 150.6 (1C, Cbenz–O),
140.4, 139.5, 134.1, 131.8 (2C), 130.1 (2C), 129.7, 129.3 (2C),
129.2 (2C), 126.4 (2C), 121.6 (2C), 121.0 (1C, CN), 109.4
(1C, C–CN), 67.8 (1C, Cthiaz–CPh), 55.4 (2C, Cpip), 47.0 (2C,
Cpip), 39.1 (1C, CH3), 37.3 (1C, CH2). MS, m/z 549.8
[M+1]+. Anal. calcd. for C30H27N7O2S: C, 65.56; H, 4.95;
N, 17.84. Found C, 65.31; H, 4.89; N, 18.15.
2.1.5.2. 4-((4-(4-(2-(4-Chlorophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
benzonitrile (8b). Pale white solid, Yield: 75%, mp 250–
251 C; IR (KBr, cm1): 3117 (CH), 2223 (C„N), 1741
(C‚O), 1190 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d
8.26 (dd, J= 7.2, 1.8 Hz, 2H, Ar–H), 7.89–7.61 (m, 9H, Ar–
H), 7.19–7.08 (m, 2H, Ar–H), 6.21 (s, 1H, S–CH–N), 3.98
(d, J= 2.8 Hz, 1H, S–CH2), 3.81 (d, J= 4.0 Hz, 1H, S–
CH2), 3.70 (br s, 4H, piperazine), 3.49 (br s, 4H, piperazine),
2.48 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 171.8
(1C, C‚O), 169.5 (1C, Ctri–O), 166.0 (1C, Ctri–Npip), 161.2
(1C, Ctri–CPh), 149.7 (1C, Cbenz–O), 140.6, 140.0, 135.4
(C–Cl), 133.3, 132.5 (2C), 130.8 (2C), 128.9 (2C), 128.4 (2C),
125.2 (2C), 120.4 (2C), 119.8 (1C, CN), 108.2 (1C, C–CN),
66.9 (1C, Cthiaz–CPh), 56.2 (2C, Cpip), 48.3 (2C, Cpip), 40.3
(1C, CH3), 37.5 (1C, CH2). MS, m/z 584.2 [M+1]
+. Anal.
calcd. for C30H26ClN7O2S: C, 61.69; H, 4.49; N, 16.79. Found
C, 61.73; H, 4.34; N, 16.43.
2.1.5.3. 4-((4-(4-(2-(4-Bromophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
benzonitrile (8c). White solid, Yield: 72%, mp 264–267 C; IR
(KBr, cm1): 3089 (CH), 2220 (C„N), 1725 (C‚O), 1235 (C–
O–C). 1H NMR (400 MHz, DMSO-d6): d 8.13 (dd, J= 6.8,
1.8 Hz, 2H, Ar–H), 7.67–7.42 (m, 9H, Ar–H), 7.25–7.12 (m,
2H, Ar–H), 6.17 (s, 1H, S–CH–N), 3.90 (d, J= 4.2 Hz, 1H,
S–CH2), 3.78 (d, J= 6.0 Hz, 1H, S–CH2), 3.67 (br s, 4H,
piperazine), 3.53 (br s, 4H, piperazine), 2.59 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.1 (1C, C‚O), 168.7
(1C, Ctri–O), 166.8 (1C, Ctri–Npip), 160.6 (1C, Ctri–CPh),
149.2 (1C, Cbenz–O), 139.9, 139.2, 133.8, 133.0 (2C), 131.2
(2C), 129.5 (2C), 129.1 (2C), 126.6 (2C), 122.7 (C–Br), 121.9
(2C), 120.1 (1C, CN), 108.8 (1C, C–CN), 66.2 (1C, Cthiaz–
CPh), 55.8 (2C, Cpip), 48.1 (2C, Cpip), 40.6 (1C, CH3), 38.4
(1C, CH2). MS, m/z 629.2 [M+1]
+. Anal. calcd. for C30H26-
BrN7O2S: C, 57.33; H, 4.17; N, 15.60. Found C, 57.82; H,
3.98; N, 15.55.
650 A.B. Patel et al.2.1.5.4. 4-((4-(4-(2-(4-Fluorophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
benzonitrile (8d). Pale yellow solid, Yield: 77%, mp 279–
283 C; IR (KBr, cm1): 3092 (CH), 2238 (C„N), 1738
(C‚O), 1221 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d
8.22 (dd, J= 6.6, 1.4 Hz, 2H, Ar–H), 7.54–7.29 (m, 9H,
Ar–H), 7.11–7.03 (m, 2H, Ar–H), 6.23 (s, 1H, S–CH–N),
3.92 (d, J= 2.8 Hz, 1H, S–CH2), 3.80 (d, J= 4.2 Hz, 1H,
S–CH2), 3.73 (br s, 4H, piperazine), 3.48 (br s, 4H, piperazine),
2.52 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.4
(1C, C‚O), 168.0 (1C, Ctri–O), 165.1 (1C, Ctri–Npip), 160.2
(1C, Ctri–CPh), 157.6 (C–F), 150.4 (1C, Cbenz–O), 139.2,
138.7, 134.6, 132.5 (2C), 131.6 (2C), 129.6 (2C), 126.4 (2C),
120.8 (2C), 119.4 (1C, CN), 114.9 (2C), 109.0 (1C, C–CN),
67.3 (1C, Cthiaz–CPh), 55.2 (2C, Cpip), 48.9 (2C, Cpip), 39.8
(1C, CH3), 38.1 (1C, CH2). MS, m/z 566.8 [M+1]
+. Anal.
calcd. for C30H26FN7O2S: C, 63.48; H, 4.62; N, 17.27. Found
C, 64.02; H, 4.87; N, 17.01.
2.1.5.5. 4-((4-(4-Methylpiperazin-1-yl)-6-(4-(2-(4-nitrophenyl)-
4-oxothiazolidin-3-yl)phenyl)-1,3,5-triazin-2-yl)oxy)benzoni-
trile (8e). Yellow solid, Yield: 70%, mp 287–288 C; IR
(KBr, cm1): 3109 (CH), 2233 (C„N), 1721 (C‚O), 1226
(C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.19 (dd,
J= 7.8, 2.4 Hz, 2H, Ar–H), 7.58–7.20 (m, 9H, Ar–H),
7.07–6.94 (m, 2H, Ar–H), 6.19 (s, 1H, S–CH–N), 3.88 (d,
J= 4.4 Hz, 1H, S–CH2), 3.82 (d, J= 5.8 Hz, 1H, S–CH2),
3.69 (br s, 4H, piperazine), 3.55 (br s, 4H, piperazine), 2.38
(s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 171.6
(1C, C‚O), 168.4 (1C, Ctri–O), 165.5 (1C, Ctri–Npip), 159.8
(1C, Ctri–CPh), 150.1 (1C, Cbenz–O), 149.1, 146.8, 139.6,
138.9, 131.6 (2C), 130.9 (2C), 129.0 (2C), 128.2 (2C), 125.9
(2C), 121.3 (2C), 119.9 (1C, CN), 109.8 (1C, C–CN), 66.9
(1C, Cthiaz–CPh), 56.3 (2C, Cpip), 48.6 (2C, Cpip), 39.5 (1C,
CH3), 38.9 (1C, CH2). MS, m/z 594 [M+1]
+. Anal. calcd.
for C30H26N8O4S: C, 60.59; H, 4.41; N, 18.84. Found C,
60.29; H, 4.27; N, 18.59.
2.1.5.6. 4-((4-(4-(2-(4-Hydroxyphenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
benzonitrile (8f). White solid, Yield: 81%, mp 239 C; IR
(KBr, cm1): 3478 (OH), 3111 (CH), 2227 (C„N), 1729
(C‚O), 1238 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d
8.31 (dd, J= 7.2, 2.2 Hz, 2H, Ar–H), 7.82–7.55 (m, 9H, Ar–
H), 7.43–7.22 (m, 2H, Ar–H), 6.20 (s, 1H, S–CH–N), 5.28
(1H, OH), 3.85 (d, J= 2.2 Hz, 1H, S–CH2), 3.78 (d,
J= 3.8 Hz, 1H, S–CH2), 3.68 (br s, 4H, piperazine), 3.49 (br
s, 4H, piperazine), 2.40 (s, 3H, CH3).
13C NMR (100 MHz,
DMSO-d6): d 170.9 (1C, C‚O), 169.5 (1C, Ctri–O), 166.3
(1C, Ctri–Npip), 159.4 (1C, Ctri–CPh), 154.8 (1C, C–OH),
149.8 (1C, Cbenz–O), 140.2, 139.4, 133.9, 132.0 (2C), 131.2
(2C), 128.7 (2C), 125.4 (2C), 121.7 (2C), 120.3 (1C, CN),
118.5 (2C), 108.7 (1C, C–CN), 67.3 (1C, Cthiaz–CPh), 56.8
(2C, Cpip), 48.2 (2C, Cpip), 39.7 (1C, CH3), 37.2 (1C, CH2).
MS, m/z 565.3 [M+1]+. Anal. calcd. for C30H27N7O3S: C,
63.70; H, 4.81; N, 17.33. Found C, 63.32; H, 4.19; N, 17.64.
2.1.5.7. 4-((4-(4-(2-(4-Methoxyphenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
benzonitrile (8g).White solid, Yield: 73%, mp 212–213 C; IR
(KBr, cm1): 3085 (CH), 2216 (C„N), 1740 (C‚O), 1229
(C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.16 (dd,J= 6.9, 2.2 Hz, 2H, Ar–H), 7.65–7.38 (m, 9H, Ar–H),
7.23–7.04 (m, 2H, Ar–H), 6.27 (s, 1H, S–CH–N), 4.43 (s,
3H, OCH3), 3.97 (d, J= 1.8 Hz, 1H, S–CH2), 3.81 (d,
J= 3.2 Hz, 1H, S–CH2), 3.74 (br s, 4H, piperazine), 3.56 (br
s, 4H, piperazine), 2.68 (s, 3H, CH3).
13C NMR (100 MHz,
DMSO-d6): d 171.8 (1C, C‚O), 169.0 (1C, Ctri–O), 165.4
(1C, Ctri–Npip), 162.5 (1C, C–OCH3), 160.8 (1C, Ctri–CPh),
149.3 (1C, Cbenz–O), 140.7, 139.9, 134.0, 133.1 (2C), 130.0
(2C), 128.7 (2C), 126.0 (2C), 120.5 (2C), 119.7 (1C, CN),
115.3 (2C), 108.2 (1C, C–CN), 68.1 (1C, Cthiaz–CPh), 58.0
(1C, OCH3), 55.9 (2C, Cpip), 47.5 (2C, Cpip), 40.0 (1C, CH3),
37.1 (1C, CH2). MS, m/z 578.9 [M+1]
+. Anal. calcd. for C31-
H29N7O3S: C, 64.23; H, 5.04; N, 16.91. Found C, 64.61; H,
4.88; N, 16.20.
2.1.5.8. 6-((4-(4-Methylpiperazin-1-yl)-6-(4-(4-oxo-2-phenyl-
thiazolidin-3-yl)phenyl)-1,3,5-triazin-2-yl)oxy)nicotinonitrile
(9a). Pale brown solid, Yield: 74%, mp 258–261 C; IR (KBr,
cm1): 3123 (CH), 2229 (C„N), 1738 (C‚O), 1240 (C–O–C).
1H NMR (400 MHz, DMSO-d6): d 8.64 (s, 1H, CH–N of ben-
zonitrile), 8.09 (dd, J= 7.6, 2.8 Hz, 1H, Ar–H), 7.65 – 7.42 (m,
5H, Ar–H), 7.28–7.09 (m, 2H, Ar–H), 6.26 (s, 1H, S–CH–N),
3.94 (d, J= 3.8 Hz, 1H, S–CH2), 3.81 (d, J= 4.0 Hz, 1H,
S–CH2), 3.68 (br s, 4H, piperazine), 3.49 (br s, 4H, piperazine),
2.45 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.8
(1C, C‚O), 168.6 (1C, Ctri–O), 164.7 (1C, Ctri–Npip), 162.1
(1C, Ctri–Npip), 159.7 (1C, Cbenz–O), 153.2, 140.5, 139.9,
138.2, 136.1, 130.6 (2C), 130.1, 129.6 (2C), 127.5 (2C), 120.9
(2C), 117.4 (1C, CN), 114.3, 105.6 (1C, C–CN), 67.2, 55.4
(2C, Cpip), 47.3 (2C, Cpip), 40.4 (1C, CH3), 38.2 (1C, –CH2).
MS, m/z 549.5 [M+1]+. Anal. calcd. for C29H26N8O2S: C,
63.26; H, 4.76; N, 20.35. Found C, 63.45; H, 4.53; N, 20.39.
2.1.5.9. 6-((4-(4-(2-(4-Chlorophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
nicotinonitrile (9b). Pale white solid, Yield: 76%, mp 226–
227 C; IR (KBr, cm1): 3057 (CH), 2234 (C„N), 1722
(C‚O), 1215 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d
8.52 (s, 1H, CH–N of benzonitrile), 8.18 (dd, J= 7.2,
1.8 Hz, 1H, Ar–H), 7.40–7.28 (m, 5H, Ar–H), 7.15–7.01 (m,
2H, Ar–H), 6.14 (s, 1H, S–CH–N), 3.91 (d, J= 6.2 Hz, 1H,
S–CH2), 3.86 (d, J= 4.8 Hz, 1H, S–CH2), 3.72 (br s, 4H,
piperazine), 3.54 (br s, 4H, piperazine), 2.32 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 170.3 (1C, C‚O), 168.2
(1C, Ctri–O), 163.9 (1C, Ctri–Npip), 163.0 (1C, Ctri–Npip),
160.1 (1C, Cbenz–O), 152.7, 140.9, 140.0, 139.4, 135.9, 134.7
(C–Cl), 129.2 (2C), 128.9 (2C), 128.4 (2C), 119.6 (2C), 116.2
(1C, CN), 113.1, 107.3 (1C, C–CN), 66.9, 55.6 (2C, Cpip),
47.9 (2C, Cpip), 39.7 (1C, CH3), 38.4 (1C, CH2). MS, m/z
583.9 [M+1]+. Anal. calcd. for C29H25ClN8O2S: C, 59.53;
H, 4.31; N, 19.15. Found C, 58.97; H, 4.54; N, 18.86.
2.1.5.10. 6-((4-(4-(2-(4-Bromophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
nicotinonitrile (9c). White solid, Yield: 71%, mp 243–246 C;
IR (KBr, cm1): 3084 (CH), 2240 (C„N), 1730 (C‚O),
1223 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.49 (s,
1H, CH–N of benzonitrile), 8.11 (dd, J= 7.4, 2.2 Hz, 1H,
Ar–H), 7.59–7.30 (m, 5H, Ar–H), 7.09–6.82 (m, 2H, Ar–H),
6.30 (s, 1H, S–CH–N), 3.83 (d, J= 4.2 Hz, 1H, S–CH2),
3.76 (d, J= 6.8 Hz, 1H, S–CH2), 3.69 (br s, 4H, pip), 3.50
(br s, 4H, piperazine), 2.62 (s, 3H, CH3).
13C NMR
Synthesis of new thiazolidin-4-one fused s-triazines 651(100 MHz, DMSO-d6): d 171.5 (1C, C‚O), 168.7 (1C,
Ctri–O), 164.2 (1C, Ctri–Npip), 163.5 (1C, Ctri–Npip), 159.3
(1C, Cbenz–O), 152.1, 141.0, 139.7, 138.8, 133.4 (2C), 129.0
(2C), 128.4 (2C), 122.0 (1C, C–Br), 120.1 (2C), 117.3 (1C,
CN), 115.4, 108.0 (1C, C–CN), 66.4, 55.9 (2C, Cpip), 47.6
(2C, Cpip), 39.2 (1C, CH3), 38.9 (1C, CH2). MS, m/z 628
[M+1]+. Anal. calcd. for C29H25BrN8O2S: C, 55.33; H,
4.00; N, 17.80. Found C, 55.65; H, 4.19; N, 17.54.2.1.5.11. 6-((4-(4-(2-(4-Fluorophenyl)-4-oxothiazolidin-3-yl)
phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)oxy)
nicotinonitrile (9d). Pale yellow solid, Yield: 73%, mp 188–
190 C; IR (KBr, cm1): 3114 (CH), 2221 (C„N), 1719
(C‚O), 1237 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d
8.60 (s, 1H, CH–N of benzonitrile), 8.08 (dd, J= 8.2,
2.8 Hz, 1H, Ar–H), 7.47–7.22 (m, 5H, Ar–H), 7.03–6.89 (m,
2H, Ar–H), 6.19 (s, 1H, S–CH–N), 3.89 (d, J= 4.0 Hz, 1H,
S–CH2), 3.80 (d, J= 6.8 Hz, 1H, S–CH2), 3.71 (br s, 4H,
piperazine), 3.55 (br s, 4H, piperazine), 2.67 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 170.7 (1C, C‚O), 168.3
(1C, Ctri–O), 164.7 (1C, Ctri–Npip), 160.9 (1C, Ctri–Npip),
159.6 (1C, Cbenz–O), 155.3 (1C, C–F), 152.8, 141.2, 140.8,
138.3, 136.0, 129.3 (2C), 127.3 (2C), 120.8 (2C), 116.9 (1C,
CN), 114.3 (2C), 113.0, 106.4 (1C, C–CN), 66.3, 56.1 (2C,
Cpip), 48.3 (2C, Cpip), 39.9 (1C, CH3), 37.2 (1C, CH2). MS,
m/z 568.1 [M+1]+. Anal. calcd. for C29H25FN8O2S: C,
61.25; H, 4.43; N, 19.71. Found C, 61.13; H, 4.50; N, 19.63.2.1.5.12. 6-((4-(4-Methylpiperazin-1-yl)-
6-(4-(2-(4-nitrophenyl)-4-oxothiazolidin-3-yl)phenyl)-
1,3,5-triazin-2-yl)oxy)nicotinonitrile (9e). Yellow solid, Yield:
69%, mp 282–285 C; IR (KBr, cm1): 3104 (CH), 2232
(C„N), 1729 (C‚O), 1220 (C–O–C). 1H NMR (400 MHz,
DMSO-d6): d 8.43 (s, 1H, CH–N of benzonitrile), 8.15 (dd,
J= 6.8, 2.0 Hz, 1H, Ar–H), 7.61–7.39 (m, 5H, Ar–H), 7.23–
7.04 (m, 2H, Ar–H), 6.21 (s, 1H, S–CH–N), 3.86 (d,
J= 2.2 Hz, 1H, S–CH2), 3.78 (d, J= 4.6 Hz, 1H, S–CH2),
3.66 (br s, 4H, piperazine), 3.48 (br s, 4H, piperazine), 2.52
(s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.9 (1C,
C‚O), 167.9 (1C, Ctri–O), 164.1 (1C, Ctri–Npip), 163.7 (1C,
Ctri–Npip), 160.4 (1C, Cbenz–O), 153.0, 148.0, 146.2, 140.6,
140.3, 139.0, 135.3, 130.4 (2C), 126.4 (2C), 122.5 (2C), 120.3
(2C), 117.6 (1C, CN), 113.8, 107.9 (1C, C–CN), 67.8, 56.7
(2C, Cpip), 47.5 (2C, Cpip), 40.2 (1C, CH3), 37.9 (1C, –CH2).
MS, m/z 594.8 [M+1]+. Anal. calcd. for C29H25N9O4S: C,
58.48; H, 4.23; N, 21.16. Found C, 58.62; H, 4.27; N, 21.51.
2.1.5.13. 6-((4-(4-(2-(4-Hydroxyphenyl)-4-oxothiazolidin-
3-yl)phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yl)
oxy)nicotinonitrile (9f). White solid, Yield: 78%, mp 256–
257 C; IR (KBr, cm1): 3483 (OH), 3119 (CH), 2237
(C„N), 1732 (C‚O), 1234 (C–O–C). 1H NMR (400 MHz,
DMSO-d6): d 8.39 (s, 1H, CH–N of benzonitrile), 8.05 (dd,
J= 8.4, 2.5 Hz, 1H, Ar–H), 7.52–7.21 (m, 5H, Ar–H), 7.01–
6.80 (m, 2H, Ar–H), 6.09 (s, 1H, S–CH–N), 5.32 (1H, OH),
3.95 (d, J= 3.4 Hz, 1H, S–CH2), 3.84 (d, J= 6.8 Hz, 1H,
S–CH2), 3.78 (br s, 4H, piperazine), 3.57 (br s, 4H, piperazine),
2.40 (s, 3H, CH3).
13C NMR (100 MHz, DMSO-d6): d 172.2
(1C, C‚O), 168.1 (1C, Ctri–O), 163.7 (1C, Ctri–Npip), 160.9
(1C, Ctri–Npip), 160.1 (1C, Cbenz–O), 155.6, 152.9, 141.3,
140.8, 135.1, 131.8, 130.1 (2C), 129.7 (2C), 119.9 (2C), 117.3(1C, CN), 114.4 (2C), 110.9, 107.3 (1C, C–CN), 67.2, 56.0
(2C, Cpip), 48.1 (2C, Cpip), 40.7 (1C, CH3), 37.6 (1C, –CH2).
MS, m/z 565.4 [M+1]+. Anal. calcd. for C29H26N8O3S: C,
61.47; H, 4.62; N, 19.78. Found C, 61.38; H, 4.49; N, 19.67.
2.1.5.14. 6-((4-(4-(2-(4-Methoxyphenyl)-4-oxothiazolidin-3-
yl)phenyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-
yl)oxy)nicotinonitrile (9g). White solid, Yield: 75%, mp 213–
214 C; IR (KBr, cm1): 2998 (CH), 2226 (C„N), 1737 (C‚O),
1249 (C–O–C). 1H NMR (400 MHz, DMSO-d6): d 8.55 (s, 1H,
CH–N of benzonitrile), 8.19 (dd, J= 7.2, 2.6 Hz, 1H, Ar–H),
7.43–7.16 (m, 5H, Ar–H), 7.04–6.79 (m, 2H, Ar–H), 6.13 (s,
1H, S–CH–N), 4.02 (3H, OCH3), 3.90 (d, J= 2.8 Hz, 1H, S–
CH2), 3.78 (d, J= 4.2 Hz, 1H, S–CH2), 3.70 (br s, 4H, pipera-
zine), 3.51 (br s, 4H, piperazine), 2.37 (s, 3H, CH3).
13C NMR
(100 MHz, DMSO-d6): d 171.6 (1C, C‚O), 168.4 (1C, Ctri–
O), 164.2 (1C, Ctri–Npip), 163.3 (1C, Ctri–Npip), 161.7 (1C, C–
OCH3), 158.3 (1C, Cbenz–O), 152.6, 140.5, 139.3, 136.7, 129.4
(2C), 128.0 (2C), 119.3 (2C), 116.0 (1C, CN), 113.5 (2C),
111.3, 102.4 (1C,C–CN), 66.1, 58.3 (1C, OCH3), 53.8 (2C, Cpip),
47.2 (2C, Cpip), 40.6 (1C, CH3), 37.9 (1C, CH2). MS, m/z 580
[M+1]+. Anal. calcd. for C30H28N8O3S: C, 62.05; H, 4.86; N,
19.30. Found C, 61.92; H, 4.70; N, 18.96.2.2. Biology
2.2.1. In vitro evaluation of antimicrobial activity
In order to determine the antimicrobial potential of the synthe-
sized analogs, two Gram-positive bacteria (Staphylococcus
aureus MTCC 96 and Bacillus cereus MTCC 430), three
Gram-negative bacteria (Escherichia coli MTCC 739,
Pseudomonas aeruginosaMTCC 741 and Klebsiella pneumoniae
MTCC 109) and two fungi (Aspergillus niger MTCC 282 and
Candida albicansMTCC 183) species were selected and assayed
in vitro using the paper disk diffusion technique for obtaining
the zone of inhibition [35] and the agar streak dilution method.
The Mueller-Hinton agar media were sterilized (autoclaved at
120 C for 30 min), poured at uniform depth of 5 mm and al-
lowed to solidify. The microbial suspension (105 CFU/mL)
(0.5 McFarland Nephelometry Standards) was streaked over
the surface of media using a sterile cotton swab to ensure even
growth of the organisms. The tested compounds were dissolved
in dimethylsulfoxide to give solutions of 3.12–50 lg/mL. Sterile
ﬁlter paper disks measuring 6.25 mm in diameter (Whatman
No. 1 ﬁlter paper), previously soaked in a known concentration
of the respective test compound in dimethylsulfoxide was placed
on the solidiﬁed nutrient agar medium that had been inoculated
with the respectivemicroorganism and the plateswere incubated
for 24 h at (37 ± 1) C. A control disk impregnated with an
equivalent amount of dimethylsulfoxide without any sample
was also used and did not produce any inhibition. Ciproﬂoxacin
and Ketoconazole (100 lg/disk) were used as control drugs for
antibacterial and antifungal activity, respectively.
MIC of the compound was determined by the agar streak
dilution method [36]. A stock solution of the synthesized com-
pound (100 lg/mL) in dimethylsulfoxide was prepared and
graded quantities of the test compounds were incorporated
in a speciﬁed quantity of molten sterile agar, i.e. nutrient agar
for evaluation of antibacterial and sabouraud dextrose agar
for antifungal activity, respectively. The medium containing
the test compound was poured into a Petri dish at a depth of
652 A.B. Patel et al.4–5 mm and allowed to solidify under aseptic conditions. A
suspension of the respective microorganism of approximately
105 CFU/mL was prepared and applied to plates with serially
diluted compounds with concentrations in the range of
3.12–50 lg/mL in dimethylsulfoxide and incubated at
(37 ± 1) C for 24 h (bacteria) or 48 h (fungi). The lowest con-
centration of the substance that prevents the development of
visible growth is considered to be the MIC value.
2.2.2. In vitro evaluation of anticancer activity
2.2.2.1. SRB assay. The cell lines were grown in RPMI 1640
medium containing 10% fetal bovine serum and 2 mM L-gluta-
mine. For present screening experiment, cells were inoculated
into 96 well microtiter plates in 90 lL at plating densities,
depending on the doubling time of individual cell lines. After
cell inoculation, the microtiter plates were incubated at
(37 ± 1) C, 5% CO2, 95% air and 100% relative humidity
for 24 h prior to addition of experimental drugs. After 24 h,
one plate of each cell line was ﬁxed in situ with TCA, to rep-
resent a measurement of the cell population for each cell line
at the time of drug addiction (Tz). Experimental drugs were
solubilized in appropriate solvent at 400-fold the desired ﬁnal
maximum test concentration and stored frozen prior to use. At
the time of drug addition, an aliquot of frozen concentrate was
thawed and diluted to 10 times the desired ﬁnal maximum test
concentration with complete medium containing test article at
a concentration of 103. Additional three, 10-fold serial dilu-
tions were made to provide a total of four drug concentrations
plus control. Aliquots of 10 lL of these different drug dilutions
were added to the appropriate microtiter wells already contain-
ing 90 lL of medium, resulting in the required ﬁnal drug con-
centrations [37].
2.2.2.2. Endpoint measurement. After compound addition,
plates were incubated at standard conditions for 48 h and as-
say was terminated by the addition of cold TCA. Cells were
ﬁxed in situ by the gentle addition of 50 lL of cold 30% (w/
v) TCA (ﬁnal concentration, 10% TCA) and incubated for
60 min at 4 C. The supernatant was discarded and the plates
were washed ﬁve times with tap water and air dried. Sulforho-
damine B (SRB) solution (50 lL) at 0.4% (w/v) in 1% acetic
acid was added to each of the wells, and plates were incubated
for 20 min at room temperature. After staining, unbound dye
was recovered and the residual dye was removed by washing
ﬁve times with 1% acetic acid. The plates were air dried.
Bound stain was subsequently eluted with 10 mM trizma base,
and the absorbance was read on an Elisa plate reader at a
wavelength of 540 nm with 690 nm reference wavelength. Per-
cent growth was calculated on a plate-by-plate basis for test
wells relative to control wells. Percent Growth was expressed
as the ratio of average absorbance of the test well to the aver-
age absorbance of the control wells ·100. Using the six absor-
bance measurements [time zero (Tz), control growth (C), and
test growth in the presence of drug at the four concentration
levels (Ti)], the percentage growth was calculated at each of
the drug concentration levels. Percentage growth inhibition
was calculated as: [(Ti  Tz)/(C  Tz)] · 100 for concentra-
tions for which TiP Tz and [(Ti  Tz)/Tz] · 100 for concen-
trations for which Ti < Tz.
The dose response parameters were calculated for each test
article. Growth inhibition of 50% (GI50) was calculated from
[(Ti  Tz)/(C  Tz)] · 100 = 50, which is the drug concentra-tion resulting in a 50% reduction in the net protein increase
(as measured by SRB staining) in control cells during the drug
incubation. The drug concentration resulting in total growth
inhibition (TGI) was calculated from Ti = Tz. The LC50 (con-
centration of drug resulting in a 50% reduction in the mea-
sured protein at the end of the drug treatment as compared
to that at the beginning) indicating a net loss of cells following
treatment is calculated from [(Ti  Tz)/Tz] · 100 = 50. Val-
ues were calculated for each of these three parameters if the le-
vel of activity was reached; however, if the effect was not
reached or was exceeded, the values for that parameter were
expressed as greater or less than the maximum or minimum
concentration tested [38].3. Results and discussion
3.1. Chemistry
The desired coupling agents, 4-(4-chloro-6-(4-methylpiperazin-
1-yl)-1,3,5-triazin-2-yloxy)benzonitrile (3a) and 6-(4-chloro-
6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yloxy)nicotinonitrile
(3b) were initially synthesized by sequential condensation of
N-methylpiperazine and 4-hydroxybenzonitrile/6-hydroxynic-
otinonitrile with 2,4,6-trichloro-1,3,5-triazine (1) as mentioned
in Scheme 1. As a preliminary explore to optimize conditions
for the synthesis of benzonitrile incorporated s-triazine deriva-
tive, 4-(4-chloro-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-
yloxy)benzonitrile (3a) with 4-aminophneylboronic acid
pinacol ester were initially designated as the model substrates.
To optimize the reaction conditions for the synthesis of benzo-
nitrile incorporated s-triazines, a series of ligands, palladium
sources, bases and solvents were screened for viability of
coupling approach. The results of reaction optimization are
summarized in Table 1.
We consequently studied the substrate scope of the inter-
molecular C–C coupling reaction by operating a feasible
catalyst system based on optimized condition. To ensure the
potency of the coupling reaction, we have preliminarily exam-
ined coupling reaction beneath procedure containing catalyst
system Pd(OAC)2, Xantphos L1, K3PO4 in DME at reﬂux
temperature. We were content to locate that these conditions
provided the most successful catalyst system for the coupling
of 4-(4-chloro-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yloxy)
benzonitrile (3a) with 4-aminophneylboronic acid pinacol es-
ter. The desired coupling product was scrutinized in 69% yield
(Table 1, entry 1). The effect of different bases on the reaction
was investigated. In disparity, replacing K3PO4 by K2CO3 de-
creased the yield drastically (entry 2). When the reaction was
carried out in the existence of KOtBu or Cs2CO3 instead of
K3PO4, exceedingly poorer yields of 57% and 63% were
obtained correspondingly (entry 3, 4). Variations on the palla-
dium source Pd2(dba)3, [PdCl(allyl)]2 and Pd(PPh3)4 gave infe-
rior yields, even with longer reaction times (entries 5-7).
However non polar solvent 1,4-dioxane gave almost similar
yield to DME (entry 8). Surprisingly, changing the solvent to
non polar solvent toluene led to the formation of 4a in 71%
yield (entry 9). Switching the solvent to other slightly polar sol-
vent such as THF, the product was afforded in slightly lower
yields (entry 10). However more polar solvent such as DMF
furnished moderate results (entry 11). An assorted set of addi-
tional bidentate phosphine ligands such as BINAP L2, Dppf
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Table 1 Optimization of a catalytic system for C–C coupling.a
Entry Pd Ligand Base Solvent Time % Yieldb
1 Pd(OAC)2 L1
c K3PO4 DME
c 17 69
2 Pd(OAC)2 L1 K2CO3 DME 28 34
3 Pd(OAC)2 L1 KO
tBu DME 21 57
4 Pd(OAC)2 L1 Cs2CO3 DME 19 63
5 Pd2(dba)3 L1 K3PO4 DME 26 42
6 [PdCl(allyl)]2 L1 K3PO4 DME 30 38
7 Pd(PPh3)4 L1 K3PO4 DME 24 58
8 Pd(OAC)2 L1 K3PO4 Dioxane 18 67
9 Pd(OAC)2 L1 K3PO4 Toluene 15 71
10 Pd(OAC)2 L1 K3PO4 THF 19 62
11 Pd(OAC)2 L1 K3PO4 DMF 21 55
12 Pd(OAC)2 L2
c K3PO4 Toluene 18 67
13 Pd(OAC)2 L3
c K3PO4 Toluene 16 82
14 Pd(OAC)2 L4
c K3PO4 Toluene 21 46
15 Pd(OAC)2 L5
c K3PO4 Toluene 19 59
16d Pd(OAC)2 L3 K3PO4 Toluene 13 89
17e Pd(OAC)2 L3 K3PO4 Toluene 14 84
a Pd: 1.5 mol%, ligand: 5.0 mol%, 3a: 1.0 mmol, 4-aminophneylboronic acid pinacol ester: 1.5 mmol, K3PO4: 1.5 mmol, solvent: 5 ml/mmol.
b Isolated yields.
c Xantphos (L1): 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, BINAP (L2): 2,20-bis(diphenylphosphino)-1,10-binaphthyl, Xphos (L3):
2-dicyclohexylphosphino-20,40,60-triisopropylbiphenyl, Dppf (L4): diphenylphosphinoferrocene, DPEphos (L5): bis(2-diphenylphosphino-
phenyl)ether, DME: dimethoxyethane, THF: tetrahydrofuran.
d The amount of the catalyst was increased from 1.6 to 3.0 mol%.
e Pd: 3.0 mol%, ligand: 5.0 mol%, 3b: 1.0 mmol, 4-aminophneylboronic acid pinacol ester: 1.5 mmol, K3PO4: 1.5 mmol, solvent: 5 ml/mmol.
Synthesis of new thiazolidin-4-one fused s-triazines 653L4 or DPEphos L5 and sterically hindered monodentate li-
gand such as Xphos L3 were examined under these conditions
to determine the efﬁcacy of ligand in supporting a catalytic
system for this transformation. As shown in entry (9, 11–15),
among the ligands tested (L1–L5), Xphos L3 proved to be
the most effective with the yield of 82% (entry 13). Further,
reaction time was reduced from 16 to 13 h by increasing the
mol% of catalyst Pd2(dba)3 from 1.6 to 3.0 mol% with the
yield of 89% (entry 16). Finally, another coupling agent 6-
(4-chloro-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-yloxy)nic-
otinonitrile (3b) gave 86% (entry 17) with above catalytic sys-
tem. After utilizing the optimized reaction conditions,
concentration was curved to ascertain the extent and the gen-
eralization of the process.Finally, the schiff base derivatives 6a–g/7a–g were further
synthesized by condensing the intermediates 4a/4b with
various aldehydes 5a–g. Cyclization of these schiff bases with
thioglycolic acid, gave desired thiazolidin-4-one derivatives
8a–g/9a–g (Scheme 2). The purity of the ﬁnal analogs was
checked by TLC and MS analysis. Spectral data IR, 1H NMR,
13C NMR and MS of the newly synthesized analogs 8a–g/9a–g
were in full agreement with their proposed structures.
3.2. Pharmacology
3.2.1. Antimicrobial activity
The in vitro results of antimicrobial activity of the newly
synthesized compounds 8a–g/9a–g are presented in Table 2
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654 A.B. Patel et al.as a minimal inhibitory concentration (MIC) and zone of
inhibition. Some of the compounds displayed moderate to
good inhibition in the range of 1.56-25 lg/mL. Here, the
Gram-positive bacteria, B. cereus and S. aureus showed rel-
ative high sensitivity toward the benzonitrile fused s-triazine
derivatives. In this view, analog 8d (MIC 3.12 lg/mL) was
50% less potent than ciproﬂoxacin (MIC 1.56 lg/mL)
against B. cereus, whereas the analog 8f (MIC 6.25 lg/mL)
exhibited moderate activity against the same organism. With
regard to the activity against S. aureus, the best activity was
displayed by compounds 8c, 8d and 8f (MIC 6.25 lg/mL).
On the other hand, investigation of antibacterial activity of
the synthesized compounds against the three Gram-negative
strains revealed that, the nicotinonitrile analogs 9a–g wereTable 2 Results of in vitro antimicrobial screening of analogs 8a–g
Entry X R Zone of inhibition in mm (MIC in
S. aureus B. cereus E. coli
8a CH H 20 (50) 18 (62.5) 21 (200
8b CH Cl 22 (25) 23 (50) 20 (62.
8c CH Br 27 (6.25) 26 (12.5) 24 (100
8d CH F 26 (6.25) 28 (3.12) 23 (62.
8e CH NO2 18 (100) 21 (62.5) 19 (100
8f CH OH 26 (6.25) 24 (6.25) 24 (200
8g CH OCH3 22 (12.5) 20 (50) 23 (200
9a N H 23 (250) 21 (100) 23 (62.
9b N Cl 24 (12.5) 20 (62.5) 22 (25)
9c N Br 25 (50) 23 (12.5) 24 (50)
9d N F 24 (62.5) 21 (62.5) 21 (25)
9e N NO2 22 (25) 21 (200) 23 (62.
9f N OH 25 (12.5) 24 (25) 27 (1.5
9g N OCH3 22 (25) 19 (62.5) 25 (6.2
Cip.b 30 (1.56) 31 (1.56) 32 (1.5
Ket.b – – –
DMSO – – –
a Each value is the mean of three independent experiments.
b Cip. = ciproﬂoxacin, Ket. = ketoconazole.more active as compared with the benzonitrile analogs.
The analog 9f was able to produce excellent growth inhibi-
tory activity against E. coli (MIC 1.56 lg/mL), which was
equipotent to the ciproﬂoxacin. However, compound 9g
(MIC 6.25 lg/mL) exhibited moderate activity against the
same organism.
Concerning the antifungal activity of the tested com-
pounds, only two benzonitrile derivatives namely, 8b and
8e showed sensitivity against mentioned fungal strains,
whereas the rest of the derivatives were reasonably active
or insensitive. The nitro- group functionalized benzonitrile
derivative 8e displayed exceptional antifungal efﬁcacy
3.12 lg/mL against C. albicans. Moreover, analogs 8b and
8e were also found to be moderately (MIC 6.25 lg/mL) ac-/9a–g.
lg/mL)a
P. aeruginosa K. pneumoniae A. niger C. albicans
) 23 (100) 20 (250) 17 (100) 21 (62.5)
5) 18 (50) 24 (62.5) 20 (100) 25 (6.25)
) 25 (62.5) 20 (100) 22 (62.5) 23 (50)
5) 23 (100) 21 (250) 23 (50) 26 (12.5)
) 21 (250) 22 (200) 24 (6.25) 26 (3.12)
) 26 (62.5) 25 (200) 20 (62.5) 25 (50)
) 19 (50) 21 (250) 23 (100) 22 (100)
5) 25 (62.5) 22 (50) 23 (50) 25 (200)
26 (12.5) 27 (25) 24 (62.5) 20 (25)
25 (62.5) 22 (12.5) 23 (100) 26 (25)
25 (50) 24 (100) 22 (25) 25 (62.5)
5) 23 (100) 21 (50) 25 (12.5) 23 (25)
6) 27 (25) 24 (12.5) 21 (50) 28 (62.5)
5) 26 (12.5) 23(12.5) 26 (50) 22 (100)
6) 33 (0.78) 33 (0.78) - -
– – 30 (1.56) 33 (1.56)
– – – –
Table 3 Results of in vitro anticancer screening of analogs 8a–g/9a–g.
Entry X R Anti PC3 cell line activitya(lg/mL)
LC50
b TGIb GI50
b
8a CH H >80 >80 >80
8b CH Cl >80 >80 >80
8c CH Br >80 >80 >80
8d CH F >80 >80 >80
8e CH NO2 >80 >80 >80
8f CH OH >80 >80 >80
8g CH OCH3 >80 >80 >80
9a N H >80 >80 >80
9b N Cl >80 >80 45.1
9c N Br >80 >80 >80
9d N F >80 >80 41.6
9e N NO2 >80 >80 >80
9f N OH >80 >80 32.1
9g N OCH3 >80 >80 >80
ADRc 58.8 18.6 <10
a Each value is the mean of three independent experiments.
b LC50 = concentration of drug causing 50% cell kill; TGI = concentration of drug causing total inhibition of cell growth; GI50 = con-
centration of drug causing 50% inhibition of cell growth.
c ADR= adriamycin, positive control compound.
Synthesis of new thiazolidin-4-one fused s-triazines 655tive against A. niger. Interestingly nicotinonitrile analog 9e
(MIC 12.5 lg/mL) displayed fair activity against the same
strain. However the synthesized analogs showed signiﬁcant
growth inhibition zone range of 28–24 mm, when compared
with standards 33–28 mm against both bacterial as well as
fungal species.
3.2.2. Anticancer activity
The activity of new compounds against prostate cancer (PC3)
cell proliferation reported in Table 3 suggests that only nicoti-
nonitrile based s-triazine compounds (9b, 9d and 9f) were ac-
tive in terms of GI50, in which the electron-donating hydroxy
group endowed compound 9f showed highest activity at
32.1 lg/mL of GI50. However, chloro- (9b) and ﬂuoro- (9d)
group functionalized analogs also indicated signiﬁcant activity
against prostate cancer PC3 cell line at GI50 value of 45.1 and
41.6 lg/mL, respectively.
4. Conclusion
In conclusion, we report an efﬁcient catalytic system for the
synthesis of various benzonitrile/nicotinonitrile and thiazoli-
din-4-one incorporated s-triazine analogs by applying Pd-
catalyzed C–C Suzuki coupling using an efﬁcient catalyst
system Pd(OAC)2, Xphos and K3PO4 as a base in toluene.
The bioassay results revealed that, most of the benzonitrile
compounds displayed an exceptional in vitro antimicrobial
activity against Gram-positive bacteria and fungal strains.
However, the nicotinonitrile derivatives displayed outstand-
ing inhibition against Gram-negative bacteria and prostate
cancer PC3 cells. It is worth concluding that insertion of
both benzonitrile and nicotinonitrile is essential to increase
the different pharmacological activities of the resultant scaf-
folds by lowering the MICs in all the cases evaluated. In
short, our ﬁndings might be beneﬁcial as they lead to
designing new potential bioactive agents.Acknowledgements
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